银屑病生物制剂及小分子抑制药治疗研究进展

被引：5

作者：

张昕

赵梓纲

李承新

机构：

[1] 解放军总医院皮肤科

来源：

中国药物应用与监测 | 2015年 / 12卷 / 06期

关键词：

银屑病; 生物制剂; 小分子抑制剂; 药品不良反应;

D O I：

暂无

中图分类号：

R758.63 [牛皮癣（银屑病）];

学科分类号：

100227 [皮肤病学];

摘要：

随着对银屑病发病机制研究的不断深入,近年来生物制剂及小分子抑制剂因其可抑制银屑病的关键发病环节而逐渐被广泛使用。本文从生物制剂及小分子抑制剂治疗的角度,对其临床相关药物的研究进展进行整理总结,为其临床应用提供依据。

引用

页码：329 / 333

页数：5

共 26 条

[1]

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment [J].

Papp, Kim ;

Leonardi, Craig ;

Menter, Alan ;

Thompson, Elizabeth H. Z. ;

Milmont, Cassandra E. ;

Kricorian, Greg ;

Nirula, Ajay ;

Klekotka, Paul .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (06) :1183-U399

[2]

Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials [J].

Langley, Richard G. ;

Elewski, Boni E. ;

Lebwohl, Mark ;

Reich, Kristian ;

Griffiths, Christopher E. M. ;

Papp, Kim ;

Puig, Lluis ;

Nakagawa, Hidemi ;

Spelman, Lynda ;

Sigurgeirsson, Bardur ;

Rivas, Enrique ;

Tsai, Tsen-Fang ;

Wasel, Norman ;

Tyring, Stephen ;

Salko, Thomas ;

Hampele, Isabelle ;

Notter, Marianne ;

Karpov, Alexander ;

Helou, Silvia ;

Papavassilis, Charis .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (04) :326-338

[3]

Targeting PKC in Human T Cells Using Sotrastaurin (AEB071) Preserves Regulatory T Cells and Prevents IL-17 Production [J].

He, Xuehui ;

Koenen, Hans J. P. M. ;

Smeets, Ruben L. ;

Keijsers, Romy ;

van Rijssen, Esther ;

Koerber, Andreas ;

van de Kerkhof, Peter C. ;

Boots, Annemieke M. H. ;

Joosten, Irma .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (04) :975-983

[4]

Tofacitinib and Other Kinase Inhibitors in the Treatment of Psoriasis [J].

Ortiz-Ibanez, K. ;

Alsina, M. M. ;

Munoz-Santos, C. .

ACTAS DERMO-SIFILIOGRAFICAS, 2013, 104 (04) :304-310

[5]

Cytokine-Based Therapy in Psoriasis [J].

Mitra, Anupam ;

Fallen, Robyn S. ;

Lima, Hermenio Cavalcante .

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2013, 44 (02) :173-182

[6]

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.[J].Andrew Palfreeman;McCann;McNamee.Drug Design; Development and Therapy.2013, defa

[7]

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.[J].Harry Dao Jr.;Vicky Ren.Clinical; Cosmetic and Investigational Dermatology.2013, defa

[8]

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study [J].

Rich, P. ;

Sigurgeirsson, B. ;

Thaci, D. ;

Ortonne, J. -P. ;

Paul, C. ;

Schopf, R. E. ;

Morita, A. ;

Roseau, K. ;

Harfst, E. ;

Guettner, A. ;

Machacek, M. ;

Papavassilis, C. .

BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) :402-411

[9]

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.[J].Naresh Punwani;Peggy Scherle;Robert Flores;Jack Shi;Jinjin Liang;Swamy Yeleswaram;Richard Levy;William Williams;Alice Gottlieb.Journal of the American Academy of Dermatology.2011, 4

[10]

Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study [J].

Schett, Georg ;

Wollenhaupt, Jurgen ;

Papp, Kim ;

Joos, Rik ;

Rodrigues, Jude F. ;

Vessey, Adele R. ;

Hu, ChiaChi ;

Stevens, Randall ;

de Vlam, Kurt L. .

ARTHRITIS AND RHEUMATISM, 2012, 64 (10) :3156-3167

← 1 2 3 →